Ruben Sebastian
@rubensebas.bsky.social
Biotech investor & board member | Covering biotech, drug development, venture capital, startups and pharma |📍New York
https://www.linkedin.com/in/rubensebastianperez/
https://www.linkedin.com/in/rubensebastianperez/
His discoveries deeply influenced my decision to pursue my PhD at @crg.eu on stem cell biology and cell fate conversions. Years later I was fortunate enough to briefly meet him at an @isscr.org Annual meeting, a true honor as I got to meet one of the great legends of modern developmental biology
October 7, 2025 at 7:16 PM
His discoveries deeply influenced my decision to pursue my PhD at @crg.eu on stem cell biology and cell fate conversions. Years later I was fortunate enough to briefly meet him at an @isscr.org Annual meeting, a true honor as I got to meet one of the great legends of modern developmental biology
This study by @lauralorenzos.bsky.social in @natcomms.nature.com is particularly relevant > expression of immune checkpoint ligands shifts between epithelial & mesenchymal tumors, suggesting combo ICB strategies are needed for treating hybrid EMT & mesenchymal tumors
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma - Nature Communications
Immune surveillance is critical to prevent the development and progression of cutaneous squamous cell carcinoma (cSCC). Here, the authors show that epithelial-mesenchymal plasticity in cancer cells is associated with changes in their immune checkpoint ligand profile during mouse cSCC progression, which dictates differential responses to immune checkpoint blockade.
www.nature.com
September 30, 2025 at 12:30 PM
This study by @lauralorenzos.bsky.social in @natcomms.nature.com is particularly relevant > expression of immune checkpoint ligands shifts between epithelial & mesenchymal tumors, suggesting combo ICB strategies are needed for treating hybrid EMT & mesenchymal tumors
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Advancing breakthrough science against #neurodegeneration is one of the greatest challenges of our time, and I’m excited to see NRG Therapeutics pushing the boundaries of #mitochondrial biology to bring new therapies for patients worldwide
#biotech #venturecapital #neuroscience
#biotech #venturecapital #neuroscience
September 8, 2025 at 10:40 PM
Advancing breakthrough science against #neurodegeneration is one of the greatest challenges of our time, and I’m excited to see NRG Therapeutics pushing the boundaries of #mitochondrial biology to bring new therapies for patients worldwide
#biotech #venturecapital #neuroscience
#biotech #venturecapital #neuroscience